No Data Yet
CorMedix has acquired Melinta Therapeutics for $300 million, a strategic move to diversify its product portfolio beyond its primary revenue driver, DefenCath. The acquisition leverages strong sales performance and reflects a broader trend of targeted M&A across the pharmaceutical and medical technology sectors.
Portfolio
